XPO1 and colorectal cancer: Recently, a novel drug (S109, a derivative of CBS9106) was shown to inhibit proliferation and arrest colorectal cancer cells by nuclear retention of tumor suppressor proteins like p21, p27 and FOXO, by reversibly binding to CRM1 and to decrease the CRM1 level using the proteasomal pathway [224].